GTx, Merck to Collaborate on the Development of SARMs
GTx and Merck have signed an agreement providing for an R&D collaboration on selective androgen receptor modulators (SARMs), a new class of drugs with the potential to treat age-related muscle loss and other musculoskeletal conditions.
This collaboration includes GTx’s lead SARM candidate, Ostarine, which is being evaluated in a Phase II trial for the treatment of muscle loss in patients with cancer, GTx said.
Under the agreement, Merck will be responsible for all future costs associated with ongoing development and, if approved, commercialization of Ostarine and other investigational SARMs resulting from the collaboration. The companies also will combine their respective SARM research programs.